Alltracel boosts Japanese firm's woundcare line:
This article was originally published in Clinica
Alltracel Pharmaceuticals has entered an agreement with Japanese consumer woundcare company Nichiban to develop and market Alltracel's m.doc "stop-bleeding" technology in Japan. The initial focus is to integrate the Dublin, Ireland-based company's SEAL.ON first aid treatment range, which incorporates m.doc's fast coagulating properties, into Nichiban's portfolio of woundcare brands. The Tokyo-based firm, which holds a 23% majority share of the Japanese consumer woundcare market, says it also plans to upgrade its own line-up of existing brands by introducing m.doc technology into the products.
You may also be interested in...
Phase I data presented at ASCO for ALLO-501 offer proof of concept for the CD19 allogeneic CAR-T and a companion drug, ALLO-647, for lymphodepletion.
Dispatches from a world turned upside down covering a possible US government investigation into BARDA contracting practices and Medicare Part D plans waiving cost sharing for COVID-19 treatments.
The US FDA requests several manufacturers recall extended-release metformin based on studies confirming a higher NDMA impurity threshhold; previous testing found no significant risks.